- A cancer-related palliative indication for baseline corticosteroids may be the driving factor for poor outcomes with immune checkpoint inhibitors (ICIs).
Why this matters
- Prior research found baseline corticosteroid use reduced ICI efficacy, but these findings suggest steroid use may be appropriate in some patients.
- 650 patients, ICI therapy for advanced NSCLC and ≥10 mg prednisone equivalent within 24 hours of immunotherapy (n=93) or 0 to
- Funding: None disclosed.
- Receiving ≥10 mg prednisone was associated with significantly lower objective response rate (P=.04) and shorter median PFS (P=.01) and median OS (P<.001 than to mg.>
- Patients receiving ≥10 mg prednisone for palliative cancer indications had significantly shorter median PFS (1.4 months) and OS (2.2 months) vs:
- ≥10 mg prednisone for cancer-unrelated reasons (4.6 months, 10.7 months; all P<.001>
- 0 to
- Single-center, retrospective study.